Department of Metabolism and Endocrinology, Endocrine and Metabolic Disease Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Adult Hospital Internal Medicine Department, Endocrine Unit, The University Teaching Hospitals, Lusaka, Zambia.
Front Endocrinol (Lausanne). 2024 Feb 14;15:1309118. doi: 10.3389/fendo.2024.1309118. eCollection 2024.
Overweight and obesity are increasing global public health problems. Mazdutide is a new dual agonist drug that can potentially reduce weight and blood glucose levels simultaneously. However, the synthesis of evidence on the efficacy and safety of this drug is scarce. Therefore, this study aimed to synthesize evidence on the efficacy and safety of Mazdutide compared to placebo on weight reduction among adults with and without diabetes.
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs). Data were retrieved from six electronic databases: PubMed, Web of Science, Scopus, Cochrane Library, ClinicalTrial.gov, and Google Scholar, and manually searched from the included references. The data were synthesized using a random effect model. This analysis was performed in the R programming language using the Meta package.
A total of seven RCTs involving 680 participants were included in this study. Mazdutide was more effective in reducing body weight (mean difference [MD]= -6.22%, 95% confidence interval [CI]: -8.02% to -4.41%, I = 90.0%), systolic blood pressure (MD = -7.57 mmHg, 95% CI: -11.17 to -3.98 mmHg, I = 46%), diastolic blood pressure (MD = -2.98 mmHg, 95% CI: -5.74 to -0.22 mmHg, I = 56%), total cholesterol (MD = -16.82%, 95% CI: -24.52 to -9.13%, I = 61%), triglycerides (MD = -43.29%, 95% CI: -61.57 to -25.01%, I = 68%), low-density lipoprotein (MD= -17.07%, 95% CI: -25.54 to -8.60%, I = 53%), and high-density lipoprotein (MD = -7.54%, 95% CI: -11.26 to -3.83%, I = 0%) than placebo. Mazdutide was associated with reduced hemoglobin A1c (HbA1c) and fasting plasma glucose in participants with type 2 diabetes. In the subgroup and meta-regression analyses, weight reduction was more significant in non-diabetics compared to diabetics, and in those who received a longer treatment duration (24 weeks) than in those on shorter durations (12-20 weeks). Participants who received Mazdutide had a higher risk of transient mild or moderate gastrointestinal side effects.
Mazdutite appears to be effective in weight reduction among patients with and without diabetes, and it has an advantage over other associated comorbidities. However, it was associated with mild or moderate gastrointestinal side effects.
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=403859, identifier CRD42023403859.
超重和肥胖是全球公共卫生的日益严重的问题。mazdutide 是一种新的双重激动剂药物，它可能同时降低体重和血糖水平。然而，关于这种药物疗效和安全性的证据综合很少。因此，本研究旨在综合评估 mazdutide 与安慰剂相比在减轻成人糖尿病和非糖尿病患者体重方面的疗效和安全性。
我们对随机对照试验（RCT）进行了系统评价和荟萃分析。数据来自 6 个电子数据库：PubMed、Web of Science、Scopus、Cochrane 图书馆、ClinicalTrials.gov 和 Google Scholar，并从纳入的参考文献中手动检索。使用随机效应模型对数据进行综合分析。该分析在 R 编程语言中使用 Meta 包进行。
共有 7 项 RCT 纳入 680 名参与者。Mazdutide 在减轻体重方面更有效（平均差异[MD]=-6.22%，95%置信区间[CI]：-8.02%至-4.41%，I=90.0%）、收缩压（MD=-7.57mmHg，95%CI：-11.17 至-3.98mmHg，I=46%）、舒张压（MD=-2.98mmHg，95%CI：-5.74 至-0.22mmHg，I=56%）、总胆固醇（MD=-16.82%，95%CI：-24.52 至-9.13%，I=61%）、甘油三酯（MD=-43.29%，95%CI：-61.57 至-25.01%，I=68%）、低密度脂蛋白（MD=-17.07%，95%CI：-25.54 至-8.60%，I=53%）和高密度脂蛋白（MD=-7.54%，95%CI：-11.26 至-3.83%，I=0%）比安慰剂。Mazdutide 与 2 型糖尿病患者的糖化血红蛋白（HbA1c）和空腹血浆葡萄糖降低有关。在亚组和荟萃回归分析中，非糖尿病患者的体重减轻比糖尿病患者更显著，且在接受较长治疗时间（24 周）的患者中比接受较短治疗时间（12-20 周）的患者更显著。接受 Mazdutide 的患者出现短暂的轻度或中度胃肠道副作用的风险较高。
Mazdutide 似乎对糖尿病和非糖尿病患者的体重减轻有效，并且对其他相关合并症有优势。然而，它与轻度或中度胃肠道副作用有关。
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=403859，标识符 CRD42023403859。
